JAK Inhibitors Lead the Way in COVID-19 Treatment Breakthroughs
Research in The Lancet shows that Janus kinase (JAK) inhibitors should be the primary treatment for hospitalized COVID-19 patients. Analysis from 16 trials indicated a 33% reduction in mortality with JAK inhibitors over other drugs. These findings emphasize the need for updated WHO guidelines.
Researchers have found that Janus kinase, or JAK, inhibitors should be the first-line therapy for COVID-19 hospitalizations, according to a study published in The Lancet Respiratory Medicine.
The analysis of nearly 13,000 patients from 16 randomized trials showed that JAK inhibitors reduced the death rate by 33% compared to other treatments like dexamethasone. Death rates stood at 11.7% for the JAK group compared to 13.2% for others.
The findings are expected to impact World Health Organization treatment guidelines. JAK inhibitors, such as Pfizer's Xeljanz, Eli Lilly's Olumiant, and AbbVie's Rinvoq, also demonstrated reduced requirements for mechanical ventilation and shorter hospital stays.
(With inputs from agencies.)
- READ MORE ON:
- JAK inhibitors
- COVID-19
- treatment
- health
- therapy
- pandemic
- research
- WHO guidelines
- Lancet
- respiratory
Advertisement
ALSO READ
ICARO-4 Spotlights Global Drive to Expand Access to Life-Saving Radiotherapy
Japan Courts U.S. Researchers Amid Policy Shifts
Smuggling Fungus: Chinese Researchers Charged as U.S.-China Tensions Rise
Researcher Faces Charges Over Smuggled Fungus, Sparking National Security Debate
Tata Memorial Centre Partners with Wipro GE for Cutting-Edge Cancer Research Hub
Google News